• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人尿激酶原酶及其活性形式的生物学和溶栓特性——I. 从人尿中获得或通过重组DNA技术制备的尿激酶在人血浆中的体外纤溶和纤维蛋白原溶解特性

Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.

作者信息

Zamarron C, Lijnen H R, Van Hoef B, Collen D

出版信息

Thromb Haemost. 1984 Aug 31;52(1):19-23.

PMID:6495259
Abstract

The fibrinolytic and fibrinogenolytic properties of recombinant pro-urokinase (Rec-pro-UK) and recombinant urokinase (Rec-UK) obtained by expression of the human urokinase cDNA in E. coli, were compared with those of natural urokinase (Nat-UK) of urinary origin and of tissue-type plasminogen activator (t-PA) in a system, composed of a radioactive human plasma clot immersed in citrated human plasma. The specific fibrinolytic effects of Nat-UK, Rec-pro-UK and Rec-UK were very similar, causing significant clot lysis at concentrations of 100 IU/ml plasma or more. t-PA caused equivalent degrees of clot lysis at 10-fold lower concentrations. Activation of the fibrinolytic system in the plasma (fibrinogenolysis), was not observed with t-PA in concentrations which induced complete clot lysis within 5 hr (20-30 IU/ml plasma). With Nat-UK and Rec-UK, all concentrations which caused significant clot lysis (100-200 IU/ml plasma) also caused extensive activation of the plasma fibrinolytic system. With Rec-pro-UK an intermediate response was obtained. The highest amounts required for complete clot lysis in 5 hr (200 IU/ml plasma) also caused significant fibrinogenolysis. At intermediate concentrations (50-100 IU/ml), however, significant clot lysis (40-80%) was observed without systemic fibrinolytic activation.

摘要

在一个由浸于枸橼酸化人血浆中的放射性人血浆凝块组成的系统中,将通过在大肠杆菌中表达人尿激酶cDNA获得的重组人尿激酶原(Rec-pro-UK)和重组尿激酶(Rec-UK)的纤溶和纤维蛋白原溶解特性,与尿源性天然尿激酶(Nat-UK)及组织型纤溶酶原激活剂(t-PA)的相应特性进行了比较。Nat-UK、Rec-pro-UK和Rec-UK的特异性纤溶作用非常相似,在血浆浓度达到100 IU/ml或更高时可引起显著的凝块溶解。t-PA在浓度低10倍时可引起同等程度的凝块溶解。在能在5小时内诱导完全凝块溶解的浓度(20 - 30 IU/ml血浆)下,t-PA未观察到血浆中纤溶系统的激活(纤维蛋白原溶解)。对于Nat-UK和Rec-UK,所有引起显著凝块溶解的浓度(100 - 200 IU/ml血浆)也会引起血浆纤溶系统的广泛激活。对于Rec-pro-UK,得到的是一种中间反应。5小时内完全凝块溶解所需的最高量(200 IU/ml血浆)也会引起显著的纤维蛋白原溶解。然而,在中等浓度(50 - 100 IU/ml)时,观察到有显著的凝块溶解(40 - 80%),但没有全身性纤溶激活。

相似文献

1
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.人尿激酶原酶及其活性形式的生物学和溶栓特性——I. 从人尿中获得或通过重组DNA技术制备的尿激酶在人血浆中的体外纤溶和纤维蛋白原溶解特性
Thromb Haemost. 1984 Aug 31;52(1):19-23.
2
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.人尿激酶原酶及活性形式的生物学和溶栓特性——IV. 几种哺乳动物血浆纤溶反应的变异性
Thromb Haemost. 1984 Aug 31;52(1):31-3.
3
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.人尿激酶原酶及其活性形式的生物学和溶栓特性——III. 天然和重组尿激酶在实验性颈静脉血栓形成兔中的溶栓特性
Thromb Haemost. 1984 Aug 31;52(1):27-30.
4
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
5
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶在体外血浆环境中对血凝块溶解不存在协同作用。
Thromb Haemost. 1986 Aug 20;56(1):35-9.
6
In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.豚鼠角膜细胞组织型纤溶酶原激活剂的纤溶、溶栓和纤维蛋白原溶解特性的体外研究。
Thromb Haemost. 1985 Apr 22;53(2):200-3.
7
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys.人尿激酶原酶及活性形式的生物学和溶栓特性——II. 兔和松鼠猴体内天然及重组尿激酶的代谢
Thromb Haemost. 1984 Aug 31;52(1):24-6.
8
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.通过在哺乳动物细胞中表达重组DNA获得的人组织型纤溶酶原激活剂的生物学特性。
J Pharmacol Exp Ther. 1984 Oct;231(1):146-52.
9
Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.标准肝素和低分子量肝素对单链尿激酶型纤溶酶原激活剂体外溶栓和纤溶活性的影响。
Thromb Haemost. 1989 Nov 24;62(3):923-6.
10
Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).通过对赖氨酸(158)位点特异性诱变产生的抗纤溶酶突变体形式的研究,对尿激酶原的内在纤溶特性进行表征。
J Clin Invest. 1988 Dec;82(6):1956-62. doi: 10.1172/JCI113815.

引用本文的文献

1
Fibrinolytic Enzymes for Thrombolytic Therapy.纤维蛋白溶解酶用于溶栓治疗。
Adv Exp Med Biol. 2019;1148:345-381. doi: 10.1007/978-981-13-7709-9_15.
2
New strategies in the development of thrombolytic agents.溶栓药物开发的新策略。
Blut. 1988 Oct;57(4):147-62. doi: 10.1007/BF00319543.